ClinicalTrials.gg
Sign In
Not yet recruitingNCT06039046Updated Sep 15, 2023

Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients

An observational study in Liposarcoma, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Power Life Sciences Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

The study seeks to delve into the firsthand experiences of patients diagnosed with liposarcoma who partake in a separate clinical research featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.

By joining this clinical study, individuals have the unique opportunity to contribute to the betterment of future liposarcoma patients and play an active role in advancing medical research.

02

Conditions studied

  • Liposarcoma

Browse trials for

Keywords

  • Liposarcoma
03

In context

Liposarcoma

160 studies on the registry are indexed under Liposarcoma; 36 are open to participants now.

This study's planned enrollment of 500 is above the median of 167 across 11 observational studies indexed under Liposarcoma.

Browse Liposarcoma studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 111 studies on the registry; 109 are open to participants now.

Browse Power Life Sciences Inc. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

People with liposarcoma who are actively considering enrolling in an observational clinical trial, but have not yet completed enrollment and randomization.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has self-identified as planning to enroll in a clinical research
  • Patient has been diagnosed with liposarcoma
  • Patient is a minimum of 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Patient does not understand, sign, and return consent form
  • Inability to perform regular electronic reporting
  • Patient is pregnant
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients who decide to participate in a liposarcoma clinical study

    Time frame: 3 months

  2. Rate of patients who remain in liposarcoma clinical study to trial completion

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Chen M, Yang J, Zhu L, Zhou C, Zhao H. Primary intrathoracic liposarcoma: a clinicopathologic study and prognostic analysis of 23 cases. J Cardiothorac Surg. 2014 Jul 4;9:119. doi: 10.1186/1749-8090-9-119. PubMed 24993036 ↗
  • Marino-Enriquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12. PubMed 24227706 ↗
  • Rossouw DJ, Cinti S, Dickersin GR. Liposarcoma. An ultrastructural study of 15 cases. Am J Clin Pathol. 1986 Jun;85(6):649-67. doi: 10.1093/ajcp/85.6.649. PubMed 3706206 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 15, 2023
StartEst.
Oct 2024
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2026
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06039046
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Oct 2024 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 15, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
4159004227
Michael B Gill
study director · Power Life Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liposarcoma →

Other studies from this sponsor

Power Life Sciences Inc. →

Start the discussion